Ken Griffin’s iTeos Therapeutics ITOS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-168,100
| Closed | -$1.68M | – | 13427 |
|
|
2025
Q2 | $1.68M | Buy |
168,100
+167,200
| +18,578% | +$1.35M | ﹤0.01% | 6051 |
|
|
2025
Q1 | $5.37K | Sell |
900
-16,900
| -95% | -$124K | ﹤0.01% | 13822 |
|
|
2024
Q4 | $137K | Sell |
17,800
-14,300
| -45% | -$123K | ﹤0.01% | 11022 |
|
|
2024
Q3 | $328K | Buy |
32,100
+8,200
| +34% | +$125K | ﹤0.01% | 9146 |
|
|
2024
Q2 | $355K | Buy |
23,900
+10,800
| +82% | +$155K | ﹤0.01% | 8796 |
|
|
2024
Q1 | $179K | Buy |
13,100
+11,000
| +524% | +$120K | ﹤0.01% | 10504 |
|
|
2023
Q4 | $23K | Sell |
2,100
-17,800
| -89% | -$176K | ﹤0.01% | 12505 |
|
|
2023
Q3 | $218K | Buy |
19,900
+17,600
| +765% | +$225K | ﹤0.01% | 9737 |
|
|
2023
Q2 | $30.5K | Buy |
2,300
+2,000
| +667% | +$28.5K | ﹤0.01% | 12341 |
|
|
2023
Q1 | $4.08K | Sell |
300
-1,600
| -84% | -$28.7K | ﹤0.01% | 13985 |
|
|
2022
Q4 | $37.1K | Sell |
1,900
-8,200
| -81% | -$160K | ﹤0.01% | 12506 |
|
|
2022
Q3 | $192K | Sell |
10,100
-15,200
| -60% | -$350K | ﹤0.01% | 10445 |
|
|
2022
Q2 | $521K | Buy |
+25,300
| New | +$600K | ﹤0.01% | 8548 |
|
Other funds holding ITOS
Ken Griffin's ITOS Position: Q3 2025 in Review
Ken Griffin sold out of iTeos Therapeutics (ITOS) in Q3 2025, closing a stake of 94,256 shares — an estimated $940K sold.
Ken Griffin first reported a position in ITOS in Q3 2020 and held it in 20 quarters. The position peaked at $46.5M in Q4 2021. 1 fund tracked by Wall St. Rank holds ITOS as of Q3 2025.
- Ken Griffin reported no remaining iTeos Therapeutics position as of Q3 2025 after selling out during the quarter.
- Ken Griffin sold 94,256 iTeos Therapeutics shares in Q3 2025, an estimated $940K.
- Ken Griffin first reported a position in iTeos Therapeutics in Q3 2020 and held it in 20 quarters.
- Ken Griffin's iTeos Therapeutics position peaked at $46.5M in Q4 2021.
- 1 fund tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2025.
Based on Citadel Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.